Financial Data and Key Metrics Changes - The company ended 2025 with cash equivalents and investments of $656.6 million, a significant increase from $198.2 million at the end of 2024 [13] - R&D expenses for 2025 were $132 million, down from $168.6 million in 2024, with Q4 2025 R&D expenses at $24.4 million compared to $44.6 million in Q4 2024 [14][15] - G&A expenses increased to $38.6 million for 2025 from $23.8 million in 2024, with Q4 2025 G&A expenses at $13.9 million compared to $7.2 million in Q4 2024 [16] - The net loss for 2025 was $154.7 million, an improvement from $177.8 million in 2024, with Q4 2025 net loss at $32.2 million compared to $48.9 million in Q4 2024 [17] Business Line Data and Key Metrics Changes - The company is focused on the development of lorundrostat, which has shown promising results in clinical trials for treating uncontrolled and resistant hypertension [5][7] - The NDA for lorundrostat was accepted by the FDA, with a PDUFA target action date set for December 22, 2026 [5] Market Data and Key Metrics Changes - Uncontrolled and resistant hypertension affects over 20 million people in the U.S., representing a significant market opportunity for lorundrostat [8] - The company is actively engaging with payers to ensure access for lorundrostat, particularly targeting its use in third-line or later treatment [21] Company Strategy and Development Direction - The company aims to position lorundrostat as a best-in-class therapy for uncontrolled and resistant hypertension, with plans for market access and payer engagement [8][9] - There is an ongoing strategy to explore additional indications for lorundrostat, including comorbid conditions related to hypertension [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market opportunity for lorundrostat, especially with the upcoming PDUFA date and the potential for a successful launch [20] - The company is optimistic about payer access and the value proposition of lorundrostat in treating resistant hypertension [21] Other Important Information - The company has expanded its medical communications efforts to support the launch of lorundrostat, including increased peer-reviewed publications and a larger team of medical science liaisons [9] Q&A Session Summary Question: What are the expectations from the competitive launch of lorundrostat? - Management is excited about the market opportunity and is observing competitor pricing and strategies to optimize lorundrostat's launch [20] Question: Can you provide insights on pre-launch payer interactions? - Management is optimistic about access, particularly for resistant hypertension, and believes the comprehensive dataset will support payer engagement [21] Question: How confident is the company in the results from the phase 2 OSA study? - Management acknowledged the study's limitations but emphasized the importance of demonstrating blood pressure reduction in high-risk patients [27][28] Question: What is the commercial capability being built ahead of the PDUFA date? - The company is making strategic investments in commercial capabilities and expanding its medical affairs team to ensure rapid uptake upon approval [38] Question: How does the company plan to differentiate its approach to market compared to competitors? - Management is evaluating the number of sales representatives needed and intends to leverage comprehensive clinical data to inform their commercial strategy [43][44] Question: What are the potential partnership opportunities being explored? - The company seeks partners that recognize the value of lorundrostat and can support its development beyond hypertension [93][94]

Financial Data and Key Metrics Changes - The company ended 2025 with cash equivalents and investments of $656.6 million, a significant increase from $198.2 million at the end of 2024 [11] - R&D expenses for 2025 were $132 million, down from $168.6 million in 2024, primarily due to a reduction in preclinical and clinical costs [12] - G&A expenses increased to $38.6 million in 2025 from $23.8 million in 2024, driven by higher compensation and professional fees [13] - The net loss for 2025 was $154.7 million, an improvement from $177.8 million in 2024 [15] Business Line Data and Key Metrics Changes - The NDA for lorundrostat was accepted by the FDA, with a PDUFA target action date set for December 22, 2026, following five positive clinical trials demonstrating its efficacy [4][5] - The company is focusing on market access planning and payer engagement to ensure the value proposition of lorundrostat is understood [6] Market Data and Key Metrics Changes - Uncontrolled and resistant hypertension affects over 20 million people in the U.S., representing a significant market opportunity for lorundrostat [6] - The company is targeting the third line or later treatment space for lorundrostat, which aligns with the needs of resistant hypertension patients [19] Company Strategy and Development Direction - The company aims to position lorundrostat as a best-in-class therapy for uncontrolled or resistant hypertension, with ongoing evaluations for further clinical development in comorbidities [9] - The strategy includes expanding medical communications and increasing peer-reviewed publications to support the launch of lorundrostat [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market opportunity for lorundrostat, especially with the upcoming competitive launch by AstraZeneca [18] - The company remains optimistic about payer access and the value proposition of lorundrostat in the resistant hypertension space [19] Other Important Information - The company is exploring additional indications for lorundrostat, particularly in conditions driven by dysregulated aldosterone, such as chronic kidney disease and obstructive sleep apnea [64] - The company is preparing for potential partnerships to maximize the value of lorundrostat, focusing on co-development opportunities [92] Q&A Session Summary Question: What insights are expected from the competitor's launch? - Management is keen to learn about pricing strategies and market positioning from the competitor's launch, emphasizing the large market opportunity for lorundrostat [18] Question: How confident is the company in payer interactions? - Management is optimistic about access, particularly for third-line treatment, and believes the comprehensive dataset will support favorable payer discussions [19] Question: What are the implications of the phase 2 OSA study results? - Management acknowledged the study's limitations but emphasized the importance of demonstrating robust blood pressure reduction in high-risk patients [26][28] Question: What is the commercial capability being built? - The company is expanding its commercial team and medical affairs capabilities to ensure a rapid uptake of lorundrostat upon approval [36] Question: How does the company view potential partnerships? - Management seeks partners that recognize the value of lorundrostat and are willing to engage in co-development opportunities [92]